Please find below a list of clinical trials available. Please click on Clinical Trial Number to link to more information.
Through a partnership with the American Association for Clinical Chemistry (AACC), the IWMF has added a terrific new resource to our web site–to help WM patients and caregivers better understand laboratory results…please see http://www.iwmf.com/about-wm/blood-tests.
This resource is Lab… Continue reading
Author(s): Paludo J, Ansell SM
Abstract: Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity characterized by the presence of a lymphoplasmacytic lymphoma, a non-Hodgkin lymphoma, and IgM monoclonal gammopathy. WM is an indolent, uncommon… Continue reading
Treatment options are limited for patients with Waldenstrom’s macroglobulinemia (WM), says Morie A. Gertz, MD. Combination therapies offer a potential solution, but the rarity of the disease is an obstacle. The disease occurs in roughly 4 patients per million, per… Continue reading
IMBRUVICA® is an oral, once-daily, single-agent therapy associated with a durable response in patients with this rare B-cell lymphoma
TORONTO, May 12, 2016 /CNW/ – Janssen Inc. announced today that Health Canada has issued… Continue reading
If you have Waldenstrom’s Macroglobulinemia (WM) or you are a caregiver of a patient with WM, you can help by completing the surveys.
Lymphoma Canada, in partnership with the Canadian Organization… Continue reading
April 4, 2016 – We are pleased to announce that Health Canada has approved Ibrutinib for WM patients in Canada. The decision was based on sponsored study data. Information has yet to be released on the funding of the… Continue reading